Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma

Cytotherapy

Volumn 9, Issue 6, 2007, Pages 539-547

  Hiwase, Devendra K ^a   Bollard, G ^b   Hiwase, S ^a   Bailey, M ^c   Muirhead, J ^b   Schwarer, A P ^b  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Cyclophosphamide; Multiple myeloma; Stem cell mobilization

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MELPHALAN; MESNA; METHYLPREDNISOLONE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CELL COUNT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INFECTION; LEUKAPHERESIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; TREATMENT DURATION;

ADULT; AGED; ANTIGENS, CD34; CELL COUNT; CYCLOPHOSPHAMIDE; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 34648816716     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240701452800     Document Type: Article

References (25)

1. Attal, M., Harousseau, JL and Stoppa, AM (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med, 335, pp. 91-97.
2. Olavarria, E. and Kanfer, EJ. (2000) Selection and use of chemotherapy with hematopoietic growth factors for mobilization of peripheral blood progenitor cells. Curr Opin Hematol, 7, pp. 191-196.
3. Boiron, JM, Marit, G. and Faberes, C. (1993) Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Bone Marrow Transplant, 12, pp. 49-55.
4. Kotasek, D., Shepherd, KM and Sage, RE (1992) Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant, 9, pp. 11-17.
5. Marit, G., Thiessard, F. and Faberes, C. (1998) Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: A monocentric study. Leukemia, 12, pp. 1447-1456.
6. Goldschmidt, H., Hegenbart, U., Haas, R. and Hunstein, W. (1996) Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant, 17, pp. 691-697.
7. Fitoussi, O., Perreau, V. and Boiron, JM (2001) A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant, 27, pp. 837-842.
8. Jantunen, E., Putkonen, M. and Nousiainen, T. (2003) Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant, 31, pp. 347-351.
9. Blade, J., Samson, D. and Reece, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT, European Group for Blood and Marrow Transplant. Br J Haematol, 102, pp. 1115-1123.
10. Bensinger, W., Appelbaum, F. and Rowley, S. (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol, 13, pp. 2547-2555.
11. Haas, R., Mohle, R. and Fruhauf, S. (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood, 83, pp. 3787-3794.
12. Tricot, G., Jagannath, S. and Vesole, D. (1995) Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood, 85, pp. 588-596.
13. Alegre, A., Tomas, JF and Martinez-Chamorro, C. (1997) Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: High-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant, 20, pp. 211-217.
14. Rowlings, PA, Bayly, JL and Rawling, CM (1992) A comparison of peripheral blood stem cell mobilisation after chemotherapy with cyclophosphamide as a single agent in doses of 4 g/m2 or 7 g/m2 in patients with advanced cancer. Aust NZ J Med, 22, pp. 660-664.
15. Demuynck, H., Delforge, M. and Verhoef, G. (1995) Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol, 90, pp. 384-392.
16. Prince, HM, Imrie, K. and Sutherland, DR (1996) Peripheral blood progenitor cell collections in multiple myeloma: Predictors and management of inadequate collections. Br J Haematol, 93, pp. 142-145.
17. Attal, M., Harousseau, JL and Facon, T. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med, 349, pp. 2495-2502.
18. Corso, A., Arcaini, L. and Caberlon, S. (2002) A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica, 87, pp. 1041-1045.
19. + cells in elderly patients (>/ = 70 years) with multiple myeloma: Influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol, 120, pp. 413-423.
20. Guba, SC, Vesole, DH and Jagannath, S. (1997) Peripheral stem cell mobilization and engraftment in patients over age 60. Bone Marrow Transplant, 20, pp. 1-3.
21. Mehta, J., Singhal, S. and Gordon, L. (2002) Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells. Bone Marrow Transplant, 29, pp. 563-567.
22. Yang, SM, Liu, KY and Lu, DP. (2005) [Comparison of the effect of Cobe Spectra and Fenwal CS 3000 plus blood cell separators in collection of peripheral blood stem cell components.]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 13, pp. 245-249.
23. Hiwase, DK, Schwarer, AP and Bollard, G. (2005) Factors influencing collection of peripheral blood stem cells (PBSC). Haematology Society of Australasia and New Zealand Annual Meeting Sydney
24. Gojo, I., Guo, C. and Sarkodee-Adoo, C. (2004) High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant, 34, pp. 69-76.
25. Min, YJ, Kim, SW and Suh, C. (2000) The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF. J Korean Med Sci, 15, pp. 49-52.